Control methods for anaplasmosis have not changed markedly during the past 50 years and include arthropod control, chemoprophylaxsis, vaccination, and maintenance of an Anaplasma‐free herd. Control measures implemented vary with geographic location, and depend on availability, cost, and the feasibility of application. Vaccination has been an effective means of preventing outbreaks of anaplasmosis, but these vaccines, both live and inactivated, are dependent on bovine blood as the source of infection or antigen. Blood‐derived vaccines are difficult to standardize and bear the risk of transmitting other bovine pathogens inapparent at the time of blood collection. Extensive purification is required to remove bovine cell membranes, which may cause side effects. Most importantly, geographic isolates of A. marginale are often not cross‐protective. Development of a tick cell culture system for A. marginale shows promise as a source of antigen for development of an improved inactivated vaccine in the near future that is free from bovine pathogens. Development of an antigenically defined molecular vaccine appears to be a realistic goal, although further research is required to determine epitopes involved in both humoral and cellular immunity, to define antigenic variation during cyclic rickettsemia, and to develop effective delivery systems for optimization of the immune response.